Topic
Propylthiouracil
About: Propylthiouracil is a research topic. Over the lifetime, 2181 publications have been published within this topic receiving 46996 citations. The topic is also known as: Thyreostat® & 2,3-dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone.
Papers published on a yearly basis
Papers
More filters
TL;DR: Another case with multiple congenital anomalies following in utero exposure to carbimazole is reported and the literature is reviewed to consider the risks and benefits of available pharmacological treatments for thyrotoxicosis in pregnancy.
Abstract: Maternal thyrotoxicosis, predominantly secondary to Graves' disease, affects 0.2% of all pregnancies. The Endocrine Society guidelines recommend the use of propylthiouracil as a first-line drug for thyrotoxicosis in pregnancy because of associations between carbimazole or methimazole and congenital anomalies. However, recent studies have highlighted the risk of severe liver injury with propylthiouracil. Here, we report another case with multiple congenital anomalies following in utero exposure to carbimazole and review the literature to consider the risks and benefits of available pharmacological treatments for thyrotoxicosis in pregnancy.
39 citations
TL;DR: A 46-yr-old postmenopausal woman with acromegaly and hyperthyroidism had serum levels of TSH which were repeatedly measurable and, therefore, inappropriately elevated and the concentration of α-subunit did not appear to vary with either T4 or TSH.
Abstract: A 46-yr-old postmenopausal woman with acromegaly and hyperthyroidism had serum levels of TSH which were repeatedly measurable (2.0-3.4 μU/ml) and, therefore, inappropriately elevated. In addition, serum concentrations of the α-subunit were persistently elevated (10.7-18.8 ng/ml). Although there was a reciprocal relationship between serum T4 and TSH levels during treatment with antithyroid drugs, the concentration of α-subunit did not appear to vary with either T4 or TSH. Transsphenoidal surgery documented the presence of a pituitary adenoma but failed to cure either the acromegaly or the hyperthyroidism. While she was hyperthyroid, α-subunit fell to 40 μU/ml, increased α-subunit fro...
38 citations
TL;DR: Spectroscopic measurement and metal analyses did not reveal the presence of flavins, hemoproteins or transition metals in stoichiometric amounts in the preparations of the enzyme, and the small amount of heme present was interpreted as being consistent with either a high degree of purification of DeGroot and Davis's previously reported apparently non-heme-containing thyroid peroxidase1.
38 citations
TL;DR: In this study, retrospectively analyzed 18 patients in whom antithyroid drug (ATD)-induced agranulocytosis developed during treatment of Graves' disease, and treatment with granulocyte-macrophage colony stimulating factor (GM-CSF) increased the granulocytes counts, whereas the effectiveness of glucocorticoid treatment was not confirmed.
Abstract: In this study, we retrospectively analyzed 18 patients in whom antithyroid drug (ATD)-induced agranulocytosis developed during treatment of Graves' disease. All patients were more than 20 years of age, and we saw no correlation between age and the development of agranulocytosis. In 17 of 18 patients, ATD-induced agranulocytosis developed within 2 to 12 weeks of starting ATD treatment. Development of agranulocytosis was related to the dose of ATD. In some patients, agranulocytosis developed abruptly, and even weekly routine WBC and granulocyte counts failed to predict all case occurrences. Fever and sore throat were the earliest symptoms of agranulocytosis; patients who developed either of these symptoms were closely monitored immediately with WBC and granulocyte count examinations. In this series of patients, treatment with granulocyte-macrophage colony stimulating factor (GM-CSF) increased the granulocyte counts, whereas the effectiveness of glucocorticoid treatment was not confirmed.
38 citations
TL;DR: The results indicated that the conversion of monoiodotyrosine to diiodotYrosine was more sensitive to propylthiouracil than the iodin, which meant that the added thyroid would have suppressed this.
Abstract: The ratio of monoiodotyrosine to diiodot3Tosine (MIT⁄DIT) and triiodothyronine to thyroxine (T3⁄T4) was increased by feeding rats propylthiouracil before the injection of I131. This change occurred even when the uptake of I131 by he thyroid had returned to normal by allowing 24 hours or more to elapse after stopping propylthiouracil or by using small amounts of propylthiouracil. A depletion of total iodine in the gland was not the cause since the MIT⁄DIT remained elevated when total iodine was preserved by adding thyroid to propylthiouracil. A high thyrotropin did not account for the result since the added thyroid would have suppressed this. A high intrathyroidal iodide was not the explanation sincethe addition of KSCN made no difference. Thyroid alone increased MIT⁄DIT probably by inhibiting the thyrotropin essential to the conversion of monoiodotyrosine to diiodotyrosine. The results indicated that the conversion of monoiodotyrosine to diiodotyrosine was more sensitive to propylthiouracil than the iodin...
38 citations